Public trial registry of the CCC-Munich

Trial AGO-OVAR2.29

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AGO-OVAR2.29
World
Full title
:

Atezolizumab in Kombination mit Bevacizumab und Chemotherapie versus Bevacizumab und Chemotherapie beim rezidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Frauenklinik GH, Telefon: 089440076800
Indications
Classification Code Description
- Gynecological tumor
ICD-10-GM C56 Bösartige Neubildung des Ovars
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Double blinded
World
Phase
:
III
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2024-12-01 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator Alexander Burges Keine Organisationseinheit angegeben Magnifier